We read with interest the paper by Pe´rez-Simo´n et al 1 on the use of meropenem as antibacterial prophylaxis after allogeneic stem cell transplantation. 1 The authors evaluated a small number of patients comparing two cohorts in a nonrandomized manner: in the first cohort (17 patients), meropenem was started on the day of the first fever, and in the second cohort (21 patients) the same antibiotic was given to afebrile neutropenic patients. They showed that the proportion of patients who developed fever was significantly lower in the group that received meropenem as prophylaxis (while afebrile). In addition, fewer patients in this group required a second-line antibiotic and the overall duration of antibiotic use was shorter. They also reported that resistance did not emerge with this strategy.
The history of antibacterial prophylaxis in neutropenic patients has been one of illusion and delusion. All strategies tested so far have had periods of great use because most studies have shown a reduction in the overall incidence of fever and Gram-negative infections.
2,3 However, after a honeymoon period, most of these strategies have been abandoned and strongly discouraged by experts 4,5 because more significant outcome variables (such as infectiousrelated death) were not influenced by these measures, [6] [7] [8] and the emergence of resistance. 9, 10 Gram-negative resistance has been a major problem in hospitalized patients worldwide, 11, 12 and the use of carbapenems has been identified as an independent risk factor for infection caused by multiresistant Gram-negative organisms. [13] [14] [15] Furthermore, among different anti-Gramnegative antibiotics, the carbapemems seem to be more associated with the development of multiresistant Pseudomonas aeruginosa. 16 Specifically in stem cell transplant recipients, in one institution where the frequency of use of b-lactam antibiotics in afebrile patients increased from less than 10% in 1991 to 57% in 1997, the frequency of streptococcal resistance to carbapenems increased from zero prior to 1996 to 25% in 1996 and 1997. 17 Considering that b-lactams are the main antibiotic class used in the empirical antibiotic therapy (a strategy that results in a significant reduction in mortality), the emergence of resistance to b-lactam antibiotics is a major concern. In the study by Pe´rez-Simo´n et al, even though the authors did not identify any resistance, the very small number of patients evaluated hampers any conclusion regarding this issue. Furthermore, the differences observed in the proportion of patients who needed modifications in the antibiotic regimen could have been due to other factors, since this is not a randomized trial. The difference observed could be related to the fact that most methicillin-resistant organisms were isolated from patients in the empirical therapy group; an imbalance that would be less likely to occur in a randomized study.
We have observed a low incidence of Gram-negative resistance among our stem cell transplant recipients. Among 245 transplants performed between 1995 and 2002, a resistant Gram-negative organism was identified as a cause of bacteremia in 4.5% of transplants (data not published). However, a multivariate analysis showed that having a bloodstream infection caused by resistant Gramnegative organisms was an independent risk factor for death in the early post-transplant period, with an odds ratio of 7.66.
In summary, although this study showed some benefit of prophylaxis like many others before it, clinically relevant outcome variables were not influenced by this strategy. In addition, its impact on the incidence of resistance was not adequately assessed. Therefore, the benefit observed may be achieved at a high price that may be evident months or years later. We think that this strategy is of limited value and should be strongly discouraged. 
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